Simple Summary Coronavirus disease 2019 (COVID-19) is the greatest present-day public
and global health challenge, and patients with cancer are especially vulnerable …

Patients with solid cancer have an increased risk of severe coronavirus disease 2019
(COVID-19) and associated mortality than the general population. This meta-analysis aimed …

Background Cancer patients have an increased risk of a severe COVID-19 infection with
higher mortality rate. This study aimed to analyze the levels of anti-SARS-CoV-2 S-RBD IgG …

The use of anti‐SARS‐CoV‐2 antibody products like tixagevimab/cilgavimab represents an
important strategy to protect immunocompromised patients with haematological …

Objectives To evaluate the serologic response to the BNT162b2 messenger ribonucleic acid
vaccine in patients with urothelial carcinoma and renal cell carcinoma. Methods Between …

Abstract Background/Aim: To prospectively evaluate the efficacy and safety of the BNT162b2
vaccine in solid cancer patients undergoing systemic chemotherapy (n= 63). Patients and …

The rapid spread of the SARS-Cov-2 virus, the increase in the number of patients with
severe COVID-19, and the high mortality rate created the basis for the production of safe and …

Recent studies have provided insights into the effect of vaccine boosters on recall immunity.
Given the limited global supply of COVID-19 vaccines, identifying vulnerable populations …

Solid cancer patients, compared to their healthy counterparts, are at a greater risk of
contracting and suffering from severe complications and poorer prognosis after COVID-19 …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been
impacting healthcare in various ways worldwide and cancer patients are greatly affected by …